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Background
The relationship between the glycated haemoglobin (HbA1c) levels and risks for dia-
betic complications in patients with type 1 (T1DM) and type 2 (T2DM) diabetes was 
Abstract 
Background: The A1c-derived average glucose examined the link between the gly-
cated haemoglobin and the estimated average glucose, and provided a linear relation 
between them. Other studies proved that, over a period of 4 months, plasma glucose 
in the preceding 30 days contribute to about 50 % to the glycated haemoglobin value 
while the other 50 % is due to the remaining 3 months altogether.
Technical details of the method: In this technical note, we propose a weighted 
method assuming that the contribution of glucose to glycated haemoglobin over 3 
months is chronologically 20 %, 30 % and 50 % respectively. A comparison is made 
with the linear regression method which uses the same estimated average glucose 
over the whole period. Results yielded by the weighted method are also compared to 
those given by the model proposed by Ladyzyński et al.
Findings: A simulation is carried out on data assumed to come from a first individual with 
nearly the same level of glucose over 3 months, a second individual who starts with high 
levels of glucose and then reaches a stabilised low level by the last month, and finally, a 
third case who had just been diagnosed with diabetes during the last month whereas he/
she had a normal glycaemia during the preceding 2 months. The weighted method gives 
more realistic values of HbA1c (7.36 %, 6.80 %, 8.49 %) than the linear regression method 
without weights which gives the same value (7.45 %) for the three cases. Another compar-
ison shows that the three values given by the weighted method are slightly smaller than 
the corresponding values given by the model of Ladyzynski et al. (7.62 %, 7.02 %, 8.8 %) 
but the relative variation is nearly the same for the three values (≈3 %).
Conclussion: Without regular self-testing and day-to-day insights, a sole HbA1c value 
can be confusing and misleading. For physicians and patients, a clear understanding 
of the relationship between the weighted average glucose and HbA1c is necessary 
in order to set an appropriate daily control depending on whether the glucose is 
stabilized over the whole period, at the beginning, at the end; or still under recurrent 
episodes of high and low levels. The measured HbA1c at a biological laboratory gives 
no indication on glucose variation. Moreover, low values of glucose may cancel high 
values and lead to a “good” average glucose and ideal glycated haemoglobin.
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established by the Diabetes Control and Complications Trial Research Group (DCCT) 
(1993, 1995) and the UK Prospective Diabetes Study Group (UKPDS) (1998a, b). More 
precisely, different epidemiologic studies and clinical trials have explored the relation-
ship between HbA1c and the average blood glucose (Hempe et  al. 2002; Nathan 2009; 
Nathan et  al. 2008; Barua et  al. 2014). In particular, the A1c-derived average glucose 
(ADAG) examined the link between HbA1c and the average glucose assessed as com-
pletely as possible with combinations of continuous glucose monitoring and frequent 
finger stick capillary glucose testing (Nathan 2009; Nathan et  al. 2008). Using a linear 
regression analysis on data collected from 507 subjects, including T1DM, T2DM and 
non diabetic people from 11 centres in the US, Europe, Africa and Asia, the ADAG 
study provided a linear relation between HbA1c and the estimated average glucose (eAG) 
(Nathan et al. 2008).
Consequently, the HbA1c assay became widely accepted and used for assessing chronic 
glycaemia (American Diabetes Association (ADA) 2015), and the quasi-totality of bio-
logical laboratories which carry out HbA1c tests worldwide, indicate that a good control 
of diabetes requires an HbA1c <7 % while an HbA1c >10 % indicates a very bad control of 
diabetes.
During the last two decades, different mathematical models were proposed to deal 
with the relationship between HbA1c and the average glucose (AG) (Temsch et al. 2008; 
Dayanand et al. 2012; Ladyzyński et al. 2008, 2011, 2014). Temsch et al. (2008) proposed 
a model respecting the decreasing contribution of older glucose levels to current HbA1c 
values using truncated Fourier series and convolution. Dayanand et  al. (2012) dealt 
with a comparison of calculated HbA1c with measured HbA1c by high Pressure Liquid 
Chromatography Method (Dayanand et  al. 2012). Ladyzyński et  al. (2008, 2011, 2014)
published a series of papers on haemoglobin glycation rate constant and validation of 
haemoglobin glycation models. In the paper on haemoglobin glycation rate constant in 
non-diabetic individuals, they proposed and used the following mathematical model 
(Ladyzyński et al. 2011):
where LS is the life span (=120 days), eAG is the average glucose supposed constant over 
the life span and k is the haemoglobin glycation rate constant.
In the paper “Validation of a haemoglobin A1c model in patients with type 1 and type 
2 diabetes and its use to go beyond the average relationship of haemoglobin A1c and 
mean glucose level”, they used the previously cited model (Eq. 2) and carried out a lin-
ear regression of the data of the simulated ADAG population (i.e., with distribution of 
the eHbA1c and eAG data identical with distribution of the data in the ADAG study) to 





= 28.7 ∗ eHbA1c (%)− 46.7







(3)eHbA1c(%) = 0.0296 ∗ eAG (mg/dl) + 2.419
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Rohlfing et al. (2002) used a linear regression on DCCT data, ending up with a rela-
tion similar to the one provided by ADAG, but referring to publications indicating that 
plasma glucose (PG) in the preceding 30  days contribute to about 50  % to the HbA1c 
value and PG from 90 to 120 days earlier contribute only to about 10 % (Rohlfing et al. 
2002). More precisely, Tahara and Shima (1993) suggested that 50 % of HbA1c is deter-
mined by the PG level during the preceding one month period and that 25 % of HbA1c 
is determined by the PG during a prior 1 month period, the remaining 25 % of HbA1c 
level is therefore determined by the PG level during the 2 months period before these 
2 months (Tahara and Shima 1993). In a response to Trevino who proposed a math-
ematical formula for HbA1c change in response to exponential PG decay (Trevino 
2006), Tahara considered a slightly different relationship between PG and HbA1c. “For 
T = 120 days, 50 % of A1C is determined by the PG level during the preceding 35 days, 
25 % by the PG level during 25 days before this period and the remaining 25 % by the PG 
level during the 2 months period before these periods” (Boutayeb and Lamlili 2015).
In a recent paper, we showed that low values of HbA1c may be dangerous under recur-
rent episodes of hypoglycaemia (Trevino 2006). In the present technical note, we pro-
pose a simulation of a “weighted” version of Eq. 3 proposed by Ladyzynski et al. (2014), 
using a corrected average glucose (wAG) over 3 months instead of the uniform eAG. 
Based on the relationship between PG and HbA1c given by Tahara and cited earlier, we 
assume that, over 3 months, the earliest, middle and recent month contribution of glu-
cose to wHbA1c is 20, 30 and 50 % respectively. The limitation to a period of 3 months 
instead of four is rather a pragmatic choice linked to the blood glucose measurement by 
diabetic patients. In fact, the simulation with 4 months with weights: 10, 15, 25 and 50 % 
yields nearly the same results as with 3 months.
Technical details of the method
Considering Eq.  3 given in the introduction section, we compute an HbA1c using a 
“weighted” average glucose (wAG) as follows:
where AGM−1, AGM−2 and AGM−3 represent the average glucose computed chrono-
logically over the preceding months to the wHbA1c test.
To see the effect of weighted average glucose, we compare the computed HbA1c 
obtained by using the formulas (Eq.  3) and (Eq.  4) on the basis of simulated data 
assumed to belong to three individuals having the same 3 months mean blood glucose 
level (170 mg/dl):
1. Individual with Steady State Control (ISSC) having an average glucose (mg/dl) nearly 
the same over the 3 months period (AGM−3 = 180, AGM−2 = 170, AGM−1 = 160),
2. Individual with Improving Control (IIC) with an average glucose (AGM−3 =  250, 
AGM−2 = 160 in mg/dl) high at the beginning of the 3 months period and normal at 
the most recent month (AGM−1 = 100 mg/dl),
3. Individual Newly Diagnosed (IND) starting with a normal average glucose 
(AGM−3 =  100, AGM−2 =  100  mg/dl) at the 1st and 2nd months and reaching a 
high level at the most recent month (AGM−1 = 310 mg/dl).
(4)wAG = 20%∗AGM−3+ 30%∗AGM−2+ 50%∗AGM−1 and wHbA1c = 0.0296∗wAG +2.419
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We are aware that using data of real patients would be more interesting than simu-
lation of hypothetical data of three patients. To overcome this shortage, we compare 
our results with those yielded by the model proposed by Ladynzinski et al. (Eq. 2), with 
k = 1.296 × 10−9 l/(mmol * s).
Results
Using Eq. 3 and the “weighted” formula given by Eq. 4, we obtain the results given in 
Table 1.
Conclusion
A comparison between the two methods used to compute HbA1c shows that for the first 
individual, the two values (7.45 % vs 7.36 %) are relatively close to each other, compared 
with the values of HbA1c obtained for the second individual (7.45 % vs 6.80 %) and the 
third one (7.45 % vs 8.49 %).
Contrarily to the first method (Eq. 3) which gives the same value of HbA1c (7.45 %) for 
the three individuals, the results provided by the second method (Eq. 4) are more real-
istic since the first individual appears to have stabilised his/her glucose over the whole 3 
months period. The second individual seems to have started with a high level of glucose 
but he/she has stabilised it during the most recent month. In opposition, the third case 
seems to have just been diagnosed with diabetes during the most recent month.
Comparing the results yielded by the proposed weighted method to those given by the 
model of Ladyzinski et al. indicates that the three values of wHbA1c (7.36 %, 6.8 % and 
8.49 %) given by Eq. 4 are slightly smaller than the corresponding values given by Eq. 2 
(7.62 %, 7.02 % and 8.8 %) but the relative variation is nearly the same for the three val-
ues (≈3 %). It should be stressed that the model of Ladyzinski et al. (Eq. 2) was obtained 
by integrating the differential equation dHbA1c(t)/dt=  −kHbA1c(t)AG(t), under the 
assumption of a constant glycemia throughout the entire life span of erythrocytes.
The “weighted” method indicates clearly that, for physicians and patients, a clear 
understanding of the relationship between wAG and wHbA1c is necessary in order to 
set an appropriate daily control depending on whether the glucose is stabilised over the 
whole period, at the beginning, at the end; or still under recurrent episodes of high and 
Table 1 A comparison of HbA1c obtained by using Eq. 3 and the weighted method (Eq. 4) 
and also a comparison of results given by Eq. 2 to those given by Eq. 4
AGM-1, AGM-2, AGM-3 represent the average glucose for the 1st, 2nd and 3rd month preceding the HbA1c test and average 
glucose for 3 months is calculated as (AGM-1 + AGM-2 + AGM-3)/3































ISSC 180 170 160 170 170 167 7.45 7.36 7.71 7.62
IIC 250 160 100 170 170 148 7.45 6.80 7.71 7.02
IND 100 100 310 170 170 205 7.45 8.49 7.71 8.80
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low levels. The measured HbA1c at a biological laboratory gives no indication on glucose 
variation. Moreover, low values of glucose may cancel high values and lead to a “good” 
average glucose and ideal glycated haemoglobin. Our simulation indicates that weighted 
HbA1c could help patients with diabetes to better control their blood glucose by going 
beyond the simple average and trying to detect the variability of glucose during the 
whole period.
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